1. Home
  2. ROMA vs RLMD Comparison

ROMA vs RLMD Comparison

Compare ROMA & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roma Green Finance Limited

ROMA

Roma Green Finance Limited

HOLD

Current Price

$9.32

Market Cap

503.9M

Sector

Finance

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$5.20

Market Cap

524.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROMA
RLMD
Founded
2018
2004
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
503.9M
524.9M
IPO Year
2022
2012

Fundamental Metrics

Financial Performance
Metric
ROMA
RLMD
Price
$9.32
$5.20
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$12.40
AVG Volume (30 Days)
13.7K
1.6M
Earning Date
12-23-2025
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
N/A
$13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
154.83
52 Week Low
$1.16
$0.55
52 Week High
$11.77
$8.00

Technical Indicators

Market Signals
Indicator
ROMA
RLMD
Relative Strength Index (RSI) 51.61 35.69
Support Level $7.56 $4.85
Resistance Level $9.75 $7.28
Average True Range (ATR) 1.00 0.39
MACD -0.03 0.01
Stochastic Oscillator 27.92 19.50

Price Performance

Historical Comparison
ROMA
RLMD

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: